Rigel licenses VEPPANU from Arvinas and Pfizer in $445M deal

Rigel Pharmaceuticals said on May 12 that it has signed an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), the newly approved oral PROTAC for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. The deal is worth about $445 million in potential value, including $70 million upfront, $15 million tied to transition activities, and up to $320 million in regulatory and commercial milestones. Rigel will take on U.S. launch and commercialization, while gaining global rights and the option to sublicense outside the U.S.; the transaction is expected to close in mid-June, pending customary clearance. (prnewswire.com)

Why it matters: For veterinary professionals, this is mostly a business signal rather than a clinical one. It shows how quickly a newly approved oncology asset can change hands when its original developers decide a third-party commercial partner is the best route to market. Arvinas and Pfizer had already said in September 2025 that they planned to out-license vepdegestrant commercialization rights, and Rigel appears to be using its recent profitability, cash position, and commercial infrastructure to expand beyond its existing portfolio. (ir.arvinas.com)

What to watch: Watch for Hart-Scott-Rodino clearance, the mid-June 2026 close, and early signs of how aggressively Rigel builds VEPPANU’s U.S. launch and any ex-U.S. sublicensing strategy. (prnewswire.com)